Preclinical safety evaluation of avasimibe in beagle dogs: An ACAT inhibitor with minimal adrenal effects

Toxicological Sciences

Volumn 59, Issue 2, 2001, Pages 324-334

  Robertson, Donald G ^a   Breider, Michael A ^a   Milad, Mark A ^a  

^a PFIZER INC   (United States)

Author keywords

ACAT inhibitor; Adrenal toxicity; Avasimibe; Dog toxicity

Indexed keywords

ACYL COENZYME A; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AVASIMIBE; BETA NAPHTHOFLAVONE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; CP 1011; CYTOCHROME P450; CYTOCHROME P450 3A; ENZYME INHIBITOR; ERYTHROMYCIN DERIVATIVE; ETHOXYRESORUFIN DEETHYLASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOME ENZYME; O DEMETHYLASE; PD 148515; PENTOXYRESORUFIN DEALKYLASE; PHENOBARBITAL; PLASMA PROTEIN; RESORUFIN DERIVATIVE; STEROID HORMONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADRENAL FUNCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; CELL VACUOLE; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; ERYTHROCYTE DEFORMABILITY; FECES ANALYSIS; FEMALE; FIBROSIS; LIVER FUNCTION; LIVER TOXICITY; MALE; MORTALITY; NONHUMAN; PHARMACODYNAMICS; SALIVATION; TOXICITY TESTING; TOXICOKINETICS; VOMITING; WEIGHT REDUCTION;

ACETATES; ADMINISTRATION, ORAL; ADRENAL GLANDS; ALANINE TRANSAMINASE; ANIMALS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; ARTERIOSCLEROSIS; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ERYTHROCYTES; FEMALE; LIVER; LONGEVITY; MALE; MICROSOMES, LIVER; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS; EMESIS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0035124368     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/59.2.324     Document Type: Article

References (25)

1. Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
2. Human aortic fibrolipid lesions: Progenitor lesions for fibrous plaques exhibiting early formation of the cholesterol-rich core
3. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions: A biochemical, morphological, and morphometric evaluation
4. Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD 132301-2, an inhibitor of acyl-CoA: Cholesterol acyltransferase
5. Subacute toxicity of a novel inhibitor of acyl-CoA: Cholesterol acyltransferase in beagle dogs
6. On the etiology of subscapular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors
7. The pathogenesis of abnormal erythrocyte morphology in burns
8. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys
9. An idiopathic febrile arteritis syndrome in the dog: Beagle pain syndrome
10. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography
11. ACAT inhibitor avasimibe lowers VLDL and TG in patients with hypertriglyceridemia
12. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT
13. Inhibitors of acyl-CoA:cholesterol acyl-transferase (ACAT) as hypocholesterolemic agents. CI-1011: An acyl sulfamate with unique cholesterol-lowering activity in animals fed non-cholesterol-supplemented diets
14. Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl-CoA: Cholesterol acyltransferase inhibitor, FR145237
15. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs
16. Hepatic microsomal induction profile of carbamic acid 2,6-bis(1-methylethyl)phenoxy]sulfonyl]2,6-bis(1-methylethyl)phenyl ester, monosodium salt (PD 138142-15), a novel lipid-regulating agent
17. Subacute and subchronic toxicology of CI-986, a novel anti-inflammatory compound
18. ACAT inhibitors: Evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents
19. ACAT Inhibitors: Potential anti-atherosclerotic agents
20. Role of acyl-CoA-cholesterol acyltransferase in cellular cholesterol metabolism
21. The mature erythrocyte
22. Clinical pharmacokinetics of CI-1011, an ACAT inhibitor
23. Cell toxicity induced by inhibition of acyl coenzyme A: Cholesterol acyltransferase and accumulation of unesterified cholesterol
24. Hepatic and adrenal toxicity of a novel lipid regulator in beagle dogs